A Phase 1 interventional study of M5049 and Placebo in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-03.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamics (PD), and explore the food effect of M5049 in healthy male and female participants.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: M5049
Drug: Placebo
Drug: M5049
Drug: Placebo
Drug: M5049
Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
Participants will receive placebo matched to M5049.
Part A: Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
Time frame: Day 1 up to Day 21
Part A: Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings
Number of participants with clinically significant changes will be reported.
Time frame: Day 1 up to Day 21
Part B: Occurrence and Severity of TEAEs and SAEs
Time frame: Day 1 up to Day 33
Part B: Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings
Number of participants with clinically significant changes will be reported.
Time frame: Day 1 up to Day 33
Part C: Maximum Observed Plasma Concentration (Cmax) of M5049
Time frame: Pre-dose up to Day 6
Part C: Time to Reach Maximum Plasma Concentration (tmax) of M5049
Time frame: Pre-dose up to Day 6
Part C: Elimination Rate Constant (λz) of M5049
Time frame: Pre-dose up to Day 6
Part C: Apparent Terminal Half-life (t1/2) of M5049
Time frame: Pre-dose up to Day 6
Part C: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M5049
Time frame: Pre-dose up to Day 6
Part C: Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf)
Time frame: Pre-dose up to Day 6
Part C: Total Body Clearance (CL/f) of M5049
Time frame: Pre-dose up to Day 6
Part C: Apparent Volume of Distribution (Vz/f) of M5049
Time frame: Pre-dose up to Day 6
Part A: Maximum Observed Blood Concentration (Cmax) of M5049
Time frame: Pre-dose up to Day 6
Part A: Time to Reach Maximum Plasma Concentration (tmax) of M5049
Time frame: Pre-dose up to Day 6
Part A: Elimination Rate Constant (λz) of M5049
Time frame: Pre-dose up to Day 6
Part A: Apparent Terminal Half-life (t1/2) of M5049
Time frame: Pre-dose up to Day 6
Part A: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M5049
Time frame: Pre-dose up to Day 6
Part A: Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf)
Time frame: Pre-dose up to Day 6
Part A: Total Body Clearance (CL/f) of M5049
Time frame: Pre-dose up to Day 6
Part A: Apparent Volume of Distribution (Vz/f) of M5049
Time frame: Pre-dose up to Day 6
Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax/D) of M5049
Time frame: Pre-dose up to Day 6
Part A: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/D) of M5049
Time frame: Pre-dose up to Day 6
Part A: Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) on Digital Holter Electrocardiograms (ECG) at Day 2
Time frame: Baseline, Day 2
Part A: Time Matched Plasma Concentration of M5049
Time frame: Pre-dose up to Day 6
Part B: Maximum Observed Blood Concentration (Cmax) of M5049
Time frame: Pre-dose up to Day 19
Part B: Time to Reach Maximum Plasma Concentration (tmax) of M5049
Time frame: Pre-dose up to Day 19
Part B: Elimination Rate Constant (λz) of M5049
Time frame: Pre-dose up to Day 19
Part B: Apparent Terminal Half-life (t1/2) of M5049
Time frame: Pre-dose up to Day 19
Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M5049
Time frame: Pre-dose up to Day 19
Part B: Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf)
Time frame: Pre-dose up to Day 19
Part B: Total Body Clearance (CL/f) of M5049
Time frame: Pre-dose up to Day 19
Part B: Apparent Volume of Distribution (Vz/f) of M5049
Time frame: Pre-dose up to Day 19
Part B: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau)
Time frame: Pre-dose up to Day 19
Part B: Accumulation Ratio for Cmax (Racc Cmax) of M5049
Time frame: Pre-dose up to Day 19
Part B: Accumulation Ratio for AUCtau(Racc AUCtau) of M5049
Time frame: Pre-dose up to Day 19
Part B: Peak trough Ratio of M5049
Time frame: Pre-dose up to Day 19
Part B: Plasma Concentration Prior to the Next Dose (C trough) of M5049
Time frame: Pre-dose up to Day 19
Part B: Dose Normalized Maximum Observed Plasma Concentration at Steady State (Cmaxss/D) of M5049
Time frame: Pre-dose up to Day 19
Part B: Dose Normalized Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau/D) of M5049
Time frame: Pre-dose up to Day 19
Part B: Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) on Digital Holter Electrocardiograms (ECG) at Day 2
Time frame: Baseline, Day 2
Part B: Time Matched Plasma Concentration of M5049
Time frame: Pre-dose up to Day 19
Part C: Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
Time frame: Day 1 up to Day 23
Part C: Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings
Number of participants with clinically significant changes will be reported.
Time frame: Day 1 up to Day 23
Ran from Sep 2018 to primary completion in Jul 2019, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enpatoran
Merck KGaA, Darmstadt, Germany →